Phase II clinical trials for inflammatory bowel disease reported no toxicity or adverse events in treated patients, though detailed safety data from these trials have not been published in peer-reviewed literature
Marsh DJ, Hollopeter G, Huszar D, Laufer R, Yagaloff KA, Fisher SL, et al
Here's an honest look at what patients report, what to realistically expect, and who benefits most
The differences between these peptides go beyond information on how well they work and include storage needs, regulatory processes, and the difficulty of making them
In clinical trials, participants taking Mazdutide exhibited a statistically significant weight reduction compared to those receiving placebo